Results 61 to 70 of about 35,703 (223)
Nanotherapies for Atherosclerosis: Targeting, Catalysis, and Energy Transduction
Advanced Healthcare Materials, EarlyView.Atherosclerosis management is hindered by poor drug targeting and plaque heterogeneity. Nanotechnology overcomes these barriers via three core strategies: (1) target‐engineered nanocarriers that achieve lesion‐specific precision via ligand modification, biomimetic camouflage, stimuli‐responsive release, and self‐propelling nanomotors; (2) catalytic ...
Yuqi Yang +4 more
wiley +1 more source
A comprehensive 1000 Genomes-based genome-wide association meta-analysis of coronary artery disease [PDF]
, 2015 Existing knowledge of genetic variants affecting risk of coronary artery disease (CAD) is largely based on genome-wide association studies (GWAS) analysis of common SNPs.
Alver, Maris +153 more
core +5 more sources
Advanced Materials, EarlyView.A cryoprotectant‐compatible nanoporous platform enables ambient‐stable and scalable delivery of gene editing therapeutics. By combining hierarchical pore architecture with optimized lyophilization chemistry, the system preserves Cas9‐RNP activity post‐freeze‐drying.
Sian Lee +8 more
wiley +1 more source
Serum sdLDL-C and cellular SREBP2-dependent cholesterol levels: Is there a challenge on targeting PCSK9? [PDF]
Journal of Medical Biochemistry, 2016 Background: Serum small dense LDL-cholesterol (sdLDLC) value is suggested to be an important risk factor for atherosclerosis. Since sdLDL-C changes may be related to PCSK9 and SREBP-2 functions, the aim of this study was to investigate correlations ...
Soltanmohammadi Elham +6 more
doaj
PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. [PDF]
, 2017 BACKGROUND: Despite the availability of effective drug therapies that reduce low-density lipoprotein (LDL)-cholesterol (LDL-C), cardiovascular disease (CVD) remains an important cause of mortality and morbidity.
Casas, Juan P +5 more
core +2 more sources
Advanced Materials, EarlyView.Helper and ionizable lipids play a crucial role in determining ApoE binding and subsequent liver tropism and LDLR‐mediated uptake. Ionizable lipids primarily govern the LDLR‐independent uptake pathway. This complementary interplay between lipid components ultimately governs LNP delivery performance and therapeutic efficacy in the liver.
Ashish Sarode +16 more
wiley +1 more source
Advanced Science, EarlyView.Phospholipid transfer protein(PLTP) plays a critical role in forming a complex with kinase A (AURKA) and P65. This interaction facilitates phosphorylation of P65 at Ser536, leading to the activation of the NF‐κB signaling pathway. Ultimately, this leads to the upregulation of downstream cytokines, including IL‐6, IL‐8, and CSF‐1, which promotes M2 ...
Xinyue Liang +14 more
wiley +1 more source
PCSK9 Functions in Atherosclerosis Are Not Limited to Plasmatic LDL-Cholesterol Regulation
Frontiers in Cardiovascular Medicine, 2021 The relevance of PCSK9 in atherosclerosis progression is demonstrated by the benefits observed in patients that have followed PCSK9-targeted therapies.
Aureli Luquero +5 more
doaj +1 more source
FoxO3 transcription factor and Sirt6 deacetylase regulate LDL-cholesterol homeostasis via control of the proprotein convertase subtilisin/kexin type 9 (Pcsk9) gene expression [PDF]
, 2013 Elevated LDL-cholesterol is a risk factor for the development of cardiovascular disease. Thus, proper control of LDL-cholesterol homeostasis is critical for organismal health.
Deng, Chu-Xia +4 more
core +1 more source
Cancer Nexus, EarlyView.ABSTRACT Lipid nanoparticles (LNPs) represent the most clinically advanced platform for RNA delivery and have enabled major breakthroughs in vaccines and gene therapies. However, their broader application is still limited by inefficient extrahepatic delivery, immunogenicity, and insufficient control over tissue‐ and cell‐specific targeting. This review
Yu Han +5 more
wiley +1 more source